IIM
REGN icon

Intact Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Intact Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,010
Closed -$2.05M – 266
2026
Q1 		$2.33M Sell
3,010
-30
-1% -$23K 0.07% 182
2025
Q4 		$2.35M Buy
3,040
+270
+10% +$183K 0.07% 179
2025
Q3 		$1.56M Buy
2,770
+490
+21% +$277K 0.05% 190
2025
Q2 		$1.2M Buy
2,280
+1,500
+192% +$837K 0.04% 217
2025
Q1 		$495K Buy
780
+280
+56% +$193K 0.02% 247
2024
Q4 		$356K Buy
+500
New +$420K 0.01% 251
2018
Q2 		– Sell
-680
Closed -$234K – 280
2018
Q1 		$234K Buy
680
+120
+21% +$41.7K 0.01% 215
2017
Q4 		$211K Buy
+560
New +$227K 0.01% 252
2017
Q3 		– Sell
-810
Closed -$398K – 263
2017
Q2 		$398K Sell
810
-150
-16% -$65.6K 0.02% 173
2017
Q1 		$372K Buy
+960
New +$356K 0.02% 186
2016
Q4 		– Sell
-560
Closed -$225K – 290
2016
Q3 		$225K Buy
+560
New +$225K 0.01% 261

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Intact Investment Management's REGN Position: Q2 2026 in Review

Intact Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 3,010 shares — an estimated $2.05M sold.

Intact Investment Management first reported a position in REGN in Q3 2016 and held it in 11 quarters. The position peaked at $2.35M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Intact Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Intact Investment Management sold 3,010 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.05M.
  • Intact Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 11 quarters.
  • Intact Investment Management's Regeneron Pharmaceuticals position peaked at $2.35M in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Intact Investment Management's 13F filing for Q2 2026, filed 20 Jul 2026.